Literature DB >> 16447112

Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.

Holly Hagan1, Mary H Latka, Jennifer V Campbell, Elizabeth T Golub, Richard S Garfein, David A Thomas, Farzana Kapadia, Steffanie A Strathdee.   

Abstract

Among 404 injection drug users aged 18-35 who tested positive for hepatitis C virus (HCV) RNA, 96% had conditions that are potentially unwarranted contraindications for HCV treatment (e.g., problem drinking, moderate-to-severe depression, and recent drug injection). Restrictive eligibility criteria may deny treatment to a large proportion of patients who could benefit from it.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16447112     DOI： 10.1086/499951

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  23 in total

1.  The beginning of a new era in understanding hepatitis C virus prevention.

Authors:  Josiah D Rich; Lynn E Taylor
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

2.  Injection drug users: the overlooked core of the hepatitis C epidemic.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

3.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

4.  Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada.

Authors:  Angelique Myles; Gerry J Mugford; Jing Zhao; Murray Krahn; Peizhong P Wang
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

5.  Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report.

Authors:  Alice Asher; Paula J Lum; Kimberly Page
Journal:  J Assoc Nurses AIDS Care       Date:  2011-04-15       Impact factor: 1.354

6.  Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE).

Authors:  Farzana Kapadia; Mary H Latka; Holly Hagan; Elizabeth T Golub; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; David L Thomas; Sebastian Bonner; Thelma Thiel; Steffanie A Strathdee
Journal:  J Urban Health       Date:  2007-01       Impact factor: 3.671

7.  Managing chronic hepatitis C in primary-care settings: more than antiviral therapy.

Authors:  Barry Zevin
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

8.  A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C.

Authors:  Mary H Latka; Holly Hagan; Farzana Kapadia; Elizabeth T Golub; Sebastian Bonner; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; Minya Pu; Dave L Thomas; Thelma K Thiel; Steffanie A Strathdee
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

9.  Treatment of chronic hepatitis C infection among current and former injection drug users within a multidisciplinary treatment model at a community health centre.

Authors:  Adam Isaiah Newman; Shelley Beckstead; David Beking; Susan Finch; Tina Knorr; Carol Lynch; Meredith MacKenzie; Daphne Mayer; Brenda Melles; Ron Shore
Journal:  Can J Gastroenterol       Date:  2013-04       Impact factor: 3.522

10.  Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study.

Authors:  Jason Grebely; Meghan D Morris; Thomas M Rice; Julie Bruneau; Andrea L Cox; Arthur Y Kim; Barbara H McGovern; Naglaa H Shoukry; Georg Lauer; Lisa Maher; Andrew R Lloyd; Margaret Hellard; Maria Prins; Gregory J Dore; Kimberly Page
Journal:  Int J Epidemiol       Date:  2012-11-30       Impact factor: 7.196
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.